ComplicationsLong&shortNCT01917253
Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation.
A study testing Standard Device for peripheral vein cannulation and Long Catheters for peripheral vein cannulation in people with Complications, run by ASL TO2 Torino at 1 site in Italy.
Trial summary
The Long and Short is a prospective, randomized, controlled, open label trial to test the complications of different device for peripheral vein cannulation, standard length (about 5 cm in length) and long catheter (about 12 cm in length), inserted with Seldinger technique. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Complications
- What is being tested?
- Standard Device for peripheral vein cannulation and Long Catheters for peripheral vein cannulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteItaly
- Study dates
- Sep 2013to Dec 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adult patients
- infusional therapy more than 72 hours
Who cannot join
- need for central venous catheter
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
MECAU-Maria Vittoria Hospital
Torino, Torino, 10141
Piero Riva, MD, +39 011 439 ext. 3359
Piero Riva, MD
About this study
Official title: Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation. A Randomized Controlled Clinical Trial to Test the Complications.
The Long and Short is a prospective, randomized, controlled, open label trial to test the complications of different device for peripheral vein cannulation, standard length (about 5 cm in length) and long catheter (about 12 cm in length), inserted with Seldinger technique.
Read the detailed description
The trial will compare the main complications: infiltration rate, phlebitis rate, occlusion and/or dislocation rate, thrombosis rate, number of percutaneous sticks, successful cannulation.
Will be made for a cost analysis.
- Conditions
- Complications
- Being tested
- Standard Device for peripheral vein cannulation, Long Catheters for peripheral vein cannulation
- Keywords
- infiltration, phlebitis, occlusion, thrombosis
- Medical subject headings
- Phlebitis, Bites and Stings, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Device for peripheral vein cannulationDevice
Long Catheters for peripheral vein cannulationDevice
| Study group | Role | What they receive |
|---|---|---|
| standard length catheter | Experimental | Standard Device for peripheral vein cannulation Receives: Device: Standard Device for peripheral vein cannulation |
| Long catheter | Experimental | Standard Device for peripheral vein cannulation Receives: Device: Long Catheters for peripheral vein cannulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
complications rate
Measured: 3 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2013 (estimated)
- Study startSep 2013
- Primary completionOct 2013 (estimated)
- Study completionDec 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ASL TO2 Torino
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tiziana De Prospo, ASL TO2 Torino
- Investigators
- Piero Riva, MD, Principal investigator, ASLTO2- MECAU- Maria Vittoria Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01917253
- Sponsor's protocol ID
- 351/007A/2013
- Acronym
- Long&short
- Status last verified
- Aug 2013
- First submitted
- 5 Aug 2013
- Last updated
- 6 Aug 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation. A Randomized Controlled Clinical Trial to Test the Complications.
- ClinicalTrials.gov ID
- NCT01917253
- Acronym / sponsor ID
- Long&short / 351/007A/2013
- Conditions
- Complications
- Keywords
- infiltration, phlebitis, occlusion, thrombosis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- ASL TO2 TorinoUniversity, hospital or other
- Study start
- Sep 2013
- Primary completion
- Oct 2013 (estimated)
- Study completion
- Dec 2013 (estimated)
- First posted
- 6 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Long and Short is a prospective, randomized, controlled, open label trial to test the complications of different device for peripheral vein cannulation, standard length (about 5 cm in length) and long catheter (about 12 cm in length), inserted with Seldinger technique.
Detailed description
The trial will compare the main complications: infiltration rate, phlebitis rate, occlusion and/or dislocation rate, thrombosis rate, number of percutaneous sticks, successful cannulation.
Will be made for a cost analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| standard length catheter | Experimental | Device: Standard Device for peripheral vein cannulationStandard Device for peripheral vein cannulation |
| Long catheter | Experimental | Device: Long Catheters for peripheral vein cannulationStandard Device for peripheral vein cannulation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- adult patients
- infusional therapy more than 72 hours
Key exclusion criteria (1 listed)
- need for central venous catheter
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Device for peripheral vein cannulation | Device | standard length catheter |
| Long Catheters for peripheral vein cannulation | Device | Long catheter |
Primary outcome
complications rate
Time frame: 3 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2013.
Related trials for Complications
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
Anastomotic Leaks, Hartmanns Stump Leakage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Piero Riva, MD principal investigator
ASLTO2- MECAU- Maria Vittoria Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Device for peripheral vein cannulation and Long Catheters for peripheral vein cannulation in people with Complications, run by ASL TO2 Torino at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Tiziana De Prospo (+39 011 439 ext. 5739, tiziana.deprospo@aslto2.piemonte.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
complications rate (time frame: 3 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2013.